COMMON DEFICIENCIES RAISED BY VARIOUS REGULATORY AGENCIES
Journal Title: International Journal of Drug Regulatory Affairs - Year 2014, Vol 2, Issue 2
Abstract
Timely Product registration is a challenge in today’s scenario. Regulatory agencies are keen in assessing CTD sections like redefining starting material of Drug substance manufacturing, Pharmaceutical development, impurities in Drug substance and Drug product, Container-closure. Common deficiencies are presented in this article.
Authors and Affiliations
Mohidekar S, Maharao V, Badjatya J. K.
Keywords
Related Articles
- EP ID EP345402
- DOI 10.22270/ijdra.v2i2.125
- Views 105
- Downloads 0
GENERIC MEDICINES REGULATION IN BRAZIL
The regulation of medicines in Brazil has proven to be one of the major concerns of government policies in recent decades. In order to improve access to quality medicines for the population, the National Drug Policy was...
REGULATORY REQUIREMENTS FOR DRUG PRODUCTS REGISTRATION IN SOUTH AFRICA
The South African Pharmaceutical market is one of the emerging markets in the world and it is important to study on how to register a drug in the promising pharmaceutical market in Africa. The MCC is the regulatory body...
A Comprehensive and Comparative study of qualification process for Drug Development tools in US, Europe, Japan and India
Drug Development Tools are methods, materials, or measures that have the potential to facilitate drug development. USFDA has specified three major drug development tools and has also given the guidelines recommending the...
DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR ESTIMATION OF LEFLUNOMIDE IN ITS PHARMACEUTICAL DOSAGE FORM
A specific, accurate, precise and robust HPTLC method has been developed for estimation of Leflunomide in its pharmaceutical dosage form. The chromatographic separation was performed using Aluminum backed precoated with...
BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower d...